Header Logo

MARIA KRISTINE GULE-MONROE

TitleAssistant Professor
InstitutionMD Anderson
DepartmentDiagnostic Radiology
Address1515 Holcombe Blvd.
Houston TX 77030
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Hamidi S, Iyer P, Dadu R, Gule-Monroe M, Maniakas A, Zafereo ME, Wang JR, Busaidy N, Cabanillas M, Hamidi S, Iyer PC, Dadu R, Gule-Monroe MK, Maniakas A, Zafereo ME, Wang JR, Busaidy NL, Cabanillas ME. Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAFV600E-Mutated Anaplastic Thyroid Carcinoma. Thyroid. 2024 Mar; 34(3):336-346. PMID: 38226606.
      Citations:    Fields:    Translation:Humans
    2. Haider AS, McCutcheon IE, Ene CI, Fuller GN, Schomer DF, Gule-Monroe M, DeMonte F, Ferguson SD, Lang FF, Prabhu SS, Raza SM, Suki D, Weinberg JS, Sawaya R. Subependymomas of the fourth ventricle: To operate or not to operate? J Clin Neurosci. 2023 Dec; 118:147-152. PMID: 37944358.
      Citations:    Fields:    Translation:Humans
    3. Gregory TA, Mastall M, Lin H, Hess KR, Yuan Y, Martin-Bejarano Garcia M, Fuller GN, Alfaro KD, Gule-Monroe MK, Huse JT, Khatua S, Rao G, Sandberg DI, Wefel JS, Yeboa DN, Paulino AC, McGovern SL, Zaky W, Mahajan A, Suki D, Weathers SP, Harrison RA, de Groot JF, Puduvalli VK, Penas-Prado M, Majd NK. Characterization of recurrence patterns and outcomes of medulloblastoma in adults: The University of Texas MD Anderson Cancer Center experience. Neurooncol Adv. 2023 Jan-Dec; 5(1):vdad032. PMID: 37114244; PMCID: PMC10129387.
      Citations:    
    4. Contrera KJ, Shakibai N, Su SY, Gule-Monroe MK, Roberts D, Brahimaj B, Williams MD, Ferrarotto R, Phan J, Gunn B, Raza S, DeMonte F, Hanna EY. Impact of Clinical Factors and Treatments on SMARCB1 (INI-1)-Deficient Sinonasal Carcinoma. Otolaryngol Head Neck Surg. 2023 08; 169(2):435-440. PMID: 36856048.
      Citations: 1     Fields:    Translation:Humans
    5. Kabraji S, Ni J, Sammons S, Li T, Van Swearingen AED, Wang Y, Pereslete A, Hsu L, DiPiro PJ, Lascola C, Moore H, Hughes M, Raghavendra AS, Gule-Monroe M, Murthy RK, Winer EP, Anders CK, Zhao JJ, Lin NU. Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases. Clin Cancer Res. 2023 01 04; 29(1):174-182. PMID: 36074155; PMCID: PMC9811155.
      Citations:    
    6. Contrera KJ, Gule-Monroe MK, Hu MI, Cabanillas ME, Busaidy NL, Dadu R, Waguespack SG, Wang JR, Maniakas A, Lai SY, Diersing J, Kwon M, Grubbs EG, Subbiah V, Williams MD, Zafereo ME. Neoadjuvant Selective RET Inhibitor for Medullary Thyroid Cancer: A Case Series. Thyroid. 2023 01; 33(1):129-132. PMID: 36503246.
      Citations: 2     Fields:    Translation:Humans
    7. Haider AS, El Ahmadieh TY, Haider M, Hatanpaa KJ, Pinho MC, Mickey BE, Sawaya R, Fuller GN, Schomer DF, Gule-Monroe M. Imaging characteristics of 4th ventricle subependymoma. Neuroradiology. 2022 Sep; 64(9):1795-1800. PMID: 35426054; PMCID: PMC9365749.
      Citations:    Fields:    
    8. Johnson JM, Chen MM, Rohren EM, Prabhu S, Chasen B, Mawlawi O, Liu HL, Gule-Monroe MK. Delayed FDG PET Provides Superior Glioblastoma Conspicuity Compared to Conventional Image Timing. Front Neurol. 2021; 12:740280. PMID: 34867723; PMCID: PMC8635110.
      Citations:    
    9. Khalil M, Zafereo M, Gule-Monroe M, Sherman SI, Bell D. Non-functional water clear cell parathyroid carcinoma masquerading as medullary thyroid carcinoma. Ann Diagn Pathol. 2021 Oct; 54:151791. PMID: 34293707.
      Citations: 1     Fields:    Translation:Humans
    10. Majd NK, Mastall M, Lin H, Dibaj SS, Hess KR, Yuan Y, Fuller GN, Alfaro KD, Gule-Monroe MK, Huse JT, Khatua S, Rao G, Sandberg DI, Wefel JS, Yeboa DN, Paulino AC, McGovern SL, Zaky W, Mahajan A, Suki D, Weathers SP, Harriso RA, De Groo JF, Puduvalli VK, Penas-Prado M, Garcia MM. Clinical characterization of adult medulloblastoma and the effect of first-line therapies on outcome; The MD Anderson Cancer Center experience. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab079. PMID: 34377987; PMCID: PMC8350154.
      Citations: 1     
    11. Al Feghali KA, Fang P, Gule-Monroe M, Milgrom S, Khoury JD, Gunther JR, Sheu T, Nair R, Ahmed S, Steiner R, Strati P, Shpall EJ, Nieto YL, Hosing C, Nastoupil LJ, Westin JR, Neelapu SS, Fowler N, Flowers C, Pinnix CC, Dabaja BS. Prognostic value of disease distribution in secondary central nervous system diffuse large B cell lymphoma treated with radiation therapy. Leuk Lymphoma. 2021 10; 62(10):2400-2407. PMID: 33942701.
      Citations:    Fields:    Translation:Humans
    12. Jozaghi Y, Zafereo M, Williams MD, Gule-Monroe MK, Wang J, Grubbs EG, Vaporciyan A, Hu MI, Busaidy N, Dadu R, Waguespack SG, Subbiah V, Cabanillas M. Neoadjuvant selpercatinib for advanced medullary thyroid cancer. Head Neck. 2021 01; 43(1):E7-E12. PMID: 33169506; PMCID: PMC7756223.
      Citations: 7     Fields:    Translation:Humans
    13. Zhou Z, Sanders JW, Johnson JM, Gule-Monroe M, Chen M, Briere TM, Wang Y, Son JB, Pagel MD, Ma J, Li J. MetNet: Computer-aided segmentation of brain metastases in post-contrast T1-weighted magnetic resonance imaging. Radiother Oncol. 2020 12; 153:189-196. PMID: 32937104.
      Citations: 2     Fields:    Translation:Humans
    14. Learned KO, Vu TH, Choi JM, Gule-Monroe MK, Pytynia KB, Ginsberg LE. Purulent chondritis of thyroid cartilage. BJR Case Rep. 2020 Sep 01; 6(3):20200013. PMID: 32922843; PMCID: PMC7465748.
      Citations:    
    15. Cabanillas ME, Dadu R, Iyer P, Wanland KB, Busaidy NL, Ying A, Gule-Monroe M, Wang JR, Zafereo M, Hofmann MC. Acquired Secondary RAS Mutation in BRAFV600E-Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors. Thyroid. 2020 09; 30(9):1288-1296. PMID: 32216548; PMCID: PMC7869871.
      Citations: 18     Fields:    Translation:Humans
    16. Zhou Z, Sanders JW, Johnson JM, Gule-Monroe MK, Chen MM, Briere TM, Wang Y, Son JB, Pagel MD, Li J, Ma J. Computer-aided Detection of Brain Metastases in T1-weighted MRI for Stereotactic Radiosurgery Using Deep Learning Single-Shot Detectors. Radiology. 2020 05; 295(2):407-415. PMID: 32181729; PMCID: PMC8287889.
      Citations: 16     Fields:    Translation:Humans
    17. Maxwell JE, Gule-Monroe MK, Subbiah V, Hu M, Perrier ND, Cabanillas ME, Lee JE, Graham PH, Cote GJ, Busaidy NL, Grubbs EG. Novel use of a Clinical Laboratory Improvements Amendments (CLIA)-certified Cyclin-Dependent Kinase N2C (CDKN2C) loss assay in?sporadic medullary thyroid carcinoma. Surgery. 2020 01; 167(1):80-86. PMID: 31648931.
      Citations: 4     Fields:    Translation:Humans
    18. Wang JR, Zafereo ME, Dadu R, Ferrarotto R, Busaidy NL, Lu C, Ahmed S, Gule-Monroe MK, Williams MD, Sturgis EM, Goepfert RP, Gross ND, Lai SY, Gunn GB, Phan J, Rosenthal DI, Fuller CD, Morrison WH, Iyer P, Cabanillas ME. Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma. Thyroid. 2019 08; 29(8):1036-1043. PMID: 31319771; PMCID: PMC6707029.
      Citations: 36     Fields:    Translation:Humans
    19. Jethanandani A, Gule-Monroe MK, Chen M, Johnson JM. Extraneural Metastases From a High-Grade Glioma (HGG) With an H3F3A G34R Mutation. Front Oncol. 2019; 9:373. PMID: 31139567; PMCID: PMC6519298.
      Citations:    
    20. Jethanandani A, Chen MM, Gule-Monroe MK, Morrison WH, Lai SY, Johnson JM. Incidental detection of oropharyngeal cancer with fluciclovine PET. Head Neck. 2019 08; 41(8):E141-E145. PMID: 31046173.
      Citations: 1     Fields:    Translation:Humans
    21. Iyer PC, Cote GJ, Hai T, Gule-Monroe M, Bui-Griffith J, Williams MD, Hess K, Hofmann MC, Dadu R, Zafereo M, Busaidy NL, Ferrarotto R, Subbiah V, Gross N, Gunn BG, Skinner HD, Garden AS, Cabanillas ME. Circulating BRAF V600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid Carcinoma. JCO Precis Oncol. 2018 Nov; 2:1-11. PMID: 35135166.
      Citations: 1     Fields:    
    22. Machol K, Jankovic J, Vijayakumar D, Burrage LC, Jain M, Lewis RA, Fuller GN, Xu M, Penas-Prado M, Gule-Monroe MK, Rosenfeld JA, Chen R, Eng CM, Yang Y, Lee BH, Moretti PM, Undiagnosed Diseases Network, Dhar SU. Atypical Alexander disease with dystonia, retinopathy, and a brain mass mimicking astrocytoma. Neurol Genet. 2018 Aug; 4(4):e248. PMID: 30046660; PMCID: PMC6055357.
      Citations: 4     
    23. Iyer PC, Dadu R, Gule-Monroe M, Busaidy NL, Ferrarotto R, Habra MA, Zafereo M, Williams MD, Gunn GB, Grosu H, Skinner HD, Sturgis EM, Gross N, Cabanillas ME. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. J Immunother Cancer. 2018 07 11; 6(1):68. PMID: 29996921; PMCID: PMC6042271.
      Citations: 64     Fields:    Translation:Humans
    24. Iyer PC, Dadu R, Ferrarotto R, Busaidy NL, Habra MA, Zafereo M, Gross N, Hess KR, Gule-Monroe M, Williams MD, Cabanillas ME. Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma. Thyroid. 2018 01; 28(1):79-87. PMID: 29161986; PMCID: PMC6425981.
      Citations: 37     Fields:    Translation:Humans
    25. Sano D, Gule MK, Rosenthal DI, Bell D, Yates J, El-Naggar AK, Myers JN. Early postoperative epidermal growth factor receptor inhibition: safety and effectiveness in inhibiting microscopic residual of oral squamous cell carcinoma in vivo. Head Neck. 2013 Mar; 35(3):321-8. PMID: 22367702; PMCID: PMC3836367.
      Citations: 3     Fields:    Translation:HumansAnimals
    26. Gule MK, Chen Y, Sano D, Frederick MJ, Zhou G, Zhao M, Milas ZL, Galer CE, Henderson YC, Jasser SA, Schwartz DL, Bankson JA, Myers JN, Lai SY. Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model. Clin Cancer Res. 2011 Apr 15; 17(8):2281-91. PMID: 21220477; PMCID: PMC3079006.
      Citations: 36     Fields:    Translation:HumansAnimalsCells
    27. Sano D, Choi S, Milas ZL, Zhou G, Galer CE, Su YW, Gule M, Zhao M, Zhu Z, Myers JN. The effect of combination anti-endothelial growth factor receptor and anti-vascular endothelial growth factor receptor 2 targeted therapy on lymph node metastasis: a study in an orthotopic nude mouse model of squamous cell carcinoma of the oral tongue. Arch Otolaryngol Head Neck Surg. 2009 Apr; 135(4):411-20. PMID: 19380367; PMCID: PMC2914603.
      Citations: 13     Fields:    Translation:Animals
    GULE-MONROE's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (121)
    Explore
    _
    Co-Authors (90)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _